BOSTON & MONTREAL, January 31, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic ...

Debate over labeling certain cancers as 'benign' or 'premalignant' instead of 'cancer' due to stigma and fear. Experts weigh in on potential impact ...

Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, “Sustained Release Compositions of Endoxifen.” The 31 claims of this new patent are ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

Discover the debate surrounding the labeling of DCIS as a cancer diagnosis and its impact on patient treatment and research ...

The American Cancer Society is looking for 100,000 Black women for a cancer study as the organization works to find out why ...

Burley initially confirmed younger sister Jacqueline was having chemotherapy treatment to combat the illness - which killed ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...

TORONTO, ON / ACCESS Newswire / / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and ...